A clinical trial listing related to cerebrolysin was updated on September 29, 2026. The study, titled "Combined Acupuncture-Based Therapy for Rehabilitation After Ischemic Stroke," is registered under identifier NCT07846488. Its current status is listed as not yet recruiting. The trial phase is listed as not applicable.
No participants have been enrolled at this stage, according to the listing. The record does not include information on results, outcomes, or enrollment timelines beyond the current status. Cerebrolysin remains classified as an unapproved compound used only in research contexts, and it is not approved for clinical use in this setting.
This update reflects only the registration status of the trial as recorded on ClinicalTrials.gov. No efficacy, safety, or outcome data have been reported as part of this update. Readers should not interpret a trial listing as evidence of therapeutic effect. Further updates will depend on when and if the study begins recruiting participants.
For additional background on this compound, readers can consult the compound overview for general context.